KN-93 hydrochloride
目录号 : GC12501
A selective inhibitor of Ca2+/calmodulin-dependent kinase type II
Cas No.:1956426-56-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment[1]: | |
|
Cell lines |
NIH 3T3 fibroblasts |
|
Preparation method |
The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
24-72 h, 24 μM |
|
Applications |
KN-93 is an inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMK-II). It inhibits fibroblast CaMK-II activity and cell growth in a dose-dependent manner, reversibly arrests cells in G1 and induces apoptosis. |
| Animal experiment [2]: | |
|
Animal models |
8-24-week-old CaMKIV TG mice |
|
Dosage form |
10 to 30 μmol/kg IP |
|
Application |
KN-93 significantly suppressed isoproterenol-induced arrhythmias in CaMKIV TG mice compared with isoproterenol-treated WT mice, indicating CaMKII is a proarrhythmic molecule in the mouse model of cardiac hypertrophy. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Tombes R M, Grant S, Westin E H, et al. G1 cell cycle arrest and apoptosis are induced in NIH 3T3 cells by KN-93, an inhibitor of CaMK-II (the multifunctional Ca2+/CaM kinase)[J]. Cell growth & differentiation: the molecular biology journal of the American Association for Cancer Research, 1995, 6(9): 1063. [2]. Wu Y, Temple J, Zhang R, et al. Calmodulin kinase II and arrhythmias in a mouse model of cardiac hypertrophy[J]. Circulation, 2002, 106(10): 1288-1293. | |
KN-93 hydrochloride is a potent inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMK II) with Ki value of 0.37μM [1].
KN-93 is an inhibitor of CaMK II. It exerts its effect by competing for the calmodulin binding site of CaMK II with IC50 value of 370nM. In isolated gastric parietal cells, KN-93 shows a potent inhibition of acid secretion induced by carbachol and histamine with IC50 values of 0.15μM and 0.3μM, respectively. It also inhibits forskolin induced aminopyrine uptake with IC50 value of 0.6μM. KN-93 is also found to have effects on the H+, K+-ATPase. 10μM KN-93 and 20μM KN-93 can inhibit 26% and 35% activity of the enzyme, respectively. Moreover, KN-93 is reported to act as an extracellular blocker of Kv channels through enhancing C-type inactivation [1, 2].
References:
[1] Mamiya N, Goldenring J R, Tsunoda Y, et al. Inhibition of Acid Secretion in Gastric Parietal Cells by the Ca2+/Calmodulin-Dependent Protein Kinase II Inhibitor KN-93. Biochemical and biophysical research communications, 1993, 195(2): 608-615.
[2] Rezazadeh S, Claydon T W, Fedida D. KN-93 (2-[N-(2-hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)] amino-N-(4-chlorocinnamyl)-N-methylbenzylamine), a calcium/calmodulin-dependent protein kinase II inhibitor, is a direct extracellular blocker of voltage-gated potassium channels. Journal of Pharmacology and Experimental Therapeutics, 2006, 317(1): 292-299.
| Cas No. | 1956426-56-4 | SDF | |
| 化学名 | (E)-N-(2-(((3-(4-chlorophenyl)allyl)(methyl)amino)methyl)phenyl)-N-(2-hydroxyethyl)-4-methoxybenzenesulfonamide hydrochloride | ||
| Canonical SMILES | CN(CC1=CC=CC=C1N(S(C2=CC=C(OC)C=C2)(=O)=O)CCO)C/C([H])=C([H])/C3=CC=C(Cl)C=C3.Cl | ||
| 分子式 | C26H30Cl2N2O4S | 分子量 | 537.5 |
| 溶解度 | ≥ 26.9mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.8605 mL | 9.3023 mL | 18.6047 mL |
| 5 mM | 0.3721 mL | 1.8605 mL | 3.7209 mL |
| 10 mM | 0.186 mL | 0.9302 mL | 1.8605 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。